ERBB2 Emerges as a New Target for Colorectal Cancer

This is the authors' abstract. We don't add key points for this paper.

Summary: ERBB2 mutations and amplifications are present in 7% of colorectal cancers. The presence of these alterations may be a marker of resistance to anti-EGFR therapy and, more importantly, could help identify patients who would benefit from ERBB2-directed therapy. Cancer Discov; 5(8); 799–801.